Market Overview

Goldman Sachs Places Centene EPS and PT Under Review

Share:
Related CNC
Earnings Scheduled For July 28, 2015
UBS Has Had Enough: Centene Upgraded To Buy On 'Underappreciated Opportunities'
Strength Seen in Molina Healthcare (MOH): Stock Up 10.9% - Tale of the Tape (Zacks)

Goldman Sachs has published a research report on Centene (NYSE: CNC) commenting on lowered guidance from new market utilization pressures.

In the report, Goldman Sachs writes, "CNC revised its 2012 EPS guidance downwards, reflecting higher than anticipated medical costs in its new Texas and Kentucky markets, as well as for its individual commercial business (Celtic). CNC now sees 2012 EPS of $1.45-$1.65 vs. prior $2.64-$2.84 and anticipates a loss for 2Q2012. We expect CNC will provide further detail at its investor day this Thursday."

Goldman Sachs has EPS and price target for Centene under review, while the stock is trading down $9.27 from Friday's $35.47 closing price.

Latest Ratings for CNC

DateFirmActionFromTo
Jul 2015UBSUpgradesNeutralBuy
Jul 2015Goldman SachsDowngradesNeutralSell
Jul 2015JefferiesUpgradesHoldBuy

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color News Guidance Reiteration Analyst Ratings

 

Related Articles (CNC)

Get Benzinga's Newsletters